- Home
- DCI vs ROIV Comparison
DCI vs ROIV Comparison
Compare DCI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- ROIV
- Stock Information
- Founded
- DCI 1915
- ROIV 2014
- Country
- DCI United States
- ROIV United Kingdom
- Employees
- DCI N/A
- ROIV N/A
- Industry
- DCI Pollution Control Equipment
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- ROIV Health Care
- Exchange
- DCI Nasdaq
- ROIV Nasdaq
- Market Cap
- DCI 8.4B
- ROIV 8.4B
- IPO Year
- DCI 1987
- ROIV N/A
- Fundamental
- Price
- DCI $70.00
- ROIV $12.36
- Analyst Decision
- DCI Hold
- ROIV Strong Buy
- Analyst Count
- DCI 4
- ROIV 10
- Target Price
- DCI $69.67
- ROIV $17.33
- AVG Volume (30 Days)
- DCI 444.2K
- ROIV 4.7M
- Earning Date
- DCI 08-28-2024
- ROIV 08-08-2024
- Dividend Yield
- DCI 1.53%
- ROIV N/A
- EPS Growth
- DCI 16.55
- ROIV N/A
- EPS
- DCI 3.38
- ROIV 5.65
- Revenue
- DCI $3,586,300,000.00
- ROIV $158,303,000.00
- Revenue This Year
- DCI $5.29
- ROIV $45.51
- Revenue Next Year
- DCI $5.64
- ROIV $37.40
- P/E Ratio
- DCI $20.76
- ROIV $2.16
- Revenue Growth
- DCI 4.53
- ROIV 101.44
- 52 Week Low
- DCI $57.05
- ROIV $8.25
- 52 Week High
- DCI $78.03
- ROIV $13.24
- Technical
- Relative Strength Index (RSI)
- DCI 38.87
- ROIV 63.24
- Support Level
- DCI $69.46
- ROIV $12.16
- Resistance Level
- DCI $70.70
- ROIV $13.06
- Average True Range (ATR)
- DCI 1.17
- ROIV 0.38
- MACD
- DCI -0.33
- ROIV 0.03
- Stochastic Oscillator
- DCI 5.12
- ROIV 56.27
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.